Progyny (NASDAQ:PGNY) Upgraded at Citizens Jmp

Citizens Jmp upgraded shares of Progyny (NASDAQ:PGNY) from a market perform rating to an outperform rating in a report released on Tuesday morning, Marketbeat reports. The firm currently has $30.00 price target on the stock.

PGNY has been the subject of several other research reports. Canaccord Genuity Group raised their price objective on shares of Progyny from $23.00 to $26.00 and gave the stock a “hold” rating in a report on Monday, November 17th. Weiss Ratings reissued a “hold (c)” rating on shares of Progyny in a report on Monday, December 29th. Zacks Research raised Progyny from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 1st. Wall Street Zen upgraded Progyny from a “hold” rating to a “buy” rating in a research report on Saturday, January 3rd. Finally, Barclays initiated coverage on Progyny in a report on Monday, December 8th. They set an “overweight” rating and a $29.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, Progyny presently has an average rating of “Moderate Buy” and an average target price of $29.36.

Progyny Price Performance

Progyny stock opened at $25.00 on Tuesday. The business has a 50 day simple moving average of $25.78 and a 200 day simple moving average of $23.28. The company has a market capitalization of $2.16 billion, a PE ratio of 39.68, a price-to-earnings-growth ratio of 1.61 and a beta of 0.93. Progyny has a one year low of $17.98 and a one year high of $28.75.

Progyny (NASDAQ:PGNY) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.06. Progyny had a return on equity of 10.71% and a net margin of 4.46%.The firm had revenue of $313.35 million during the quarter, compared to analyst estimates of $299.23 million. During the same period in the prior year, the company posted $0.11 earnings per share. The business’s revenue for the quarter was up 9.3% compared to the same quarter last year. Progyny has set its FY 2025 guidance at 1.790-1.820 EPS and its Q4 2025 guidance at 0.370-0.400 EPS. Equities analysts anticipate that Progyny will post 0.6 earnings per share for the current fiscal year.

Insider Buying and Selling at Progyny

In other news, CEO Peter Anevski purchased 79,500 shares of the business’s stock in a transaction dated Thursday, November 13th. The shares were acquired at an average price of $24.29 per share, with a total value of $1,931,055.00. Following the completion of the purchase, the chief executive officer directly owned 680,251 shares of the company’s stock, valued at $16,523,296.79. The trade was a 13.23% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Mark S. Livingston sold 21,303 shares of the firm’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $25.50, for a total value of $543,226.50. Following the completion of the transaction, the chief financial officer owned 48,358 shares in the company, valued at approximately $1,233,129. This represents a 30.58% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 22,046 shares of company stock valued at $561,691 over the last three months. Insiders own 9.40% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its stake in shares of Progyny by 2.4% in the 3rd quarter. Vanguard Group Inc. now owns 10,106,147 shares of the company’s stock valued at $217,484,000 after purchasing an additional 235,513 shares during the last quarter. Ameriprise Financial Inc. boosted its stake in Progyny by 37.6% in the second quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock valued at $43,933,000 after acquiring an additional 545,431 shares during the last quarter. ArrowMark Colorado Holdings LLC boosted its stake in Progyny by 2.1% in the third quarter. ArrowMark Colorado Holdings LLC now owns 1,931,249 shares of the company’s stock valued at $41,560,000 after acquiring an additional 39,666 shares during the last quarter. Fort Washington Investment Advisors Inc. OH grew its holdings in Progyny by 10.7% during the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 1,834,104 shares of the company’s stock worth $47,100,000 after acquiring an additional 177,546 shares during the period. Finally, Barclays PLC grew its holdings in Progyny by 79.2% during the 3rd quarter. Barclays PLC now owns 1,575,470 shares of the company’s stock worth $33,904,000 after acquiring an additional 696,447 shares during the period. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.